SCHEMBL4990741

SCHEMBL4990741

CCN1CCN(c2ccc(N/C=C3/C(=O)Nc4ccc(F)cc43)cc2C(F)(F)F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 3/20 0.44
CHRM4 P08173 2/20 0.41
CHRM1 P11229 2/20 0.41
CHRM2 P08172 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM3 P20309 1/20 0.41
HSD11B1 P28845 1/20 0.40
FLT3 P36888 6/20 0.40
PDGFRB P09619 4/20 0.39
KDR P35968 4/20 0.39
CSF1R P07333 3/20 0.39
FLT1 P17948 2/20 0.39
PDGFRA P16234 2/20 0.39
FGFR1 P11362 3/20 0.37
MAPT P10636 2/20 0.37
TLK2 Q86UE8 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KCNH2 Q12809 2/20 0.37
CHEK1 O14757 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4990748 1.00 NTRK1 (0.44) NTRK1CHRM4CHRM1CHRM2CHRM5
SCHEMBL4999266 0.91 NTRK1 (0.42) NTRK1FLT3PDGFRBKDRCSF1R
SCHEMBL4999271 0.91 NTRK1 (0.42) NTRK1FLT3PDGFRBKDRCSF1R
SCHEMBL4991648 0.91 NTRK1 (0.45) NTRK1CHRM1FLT3PDGFRBKDR
SCHEMBL4991655 0.91 NTRK1 (0.45) NTRK1CHRM1FLT3PDGFRBKDR
SCHEMBL4992022 0.89 NTRK1 (0.45) NTRK1HSD11B1FLT3PDGFRBKDR
SCHEMBL4996677 0.89 FLT3 (0.40) CHRM1FLT3PDGFRBKDRCSF1R
SCHEMBL4996674 0.89 FLT3 (0.40) CHRM1FLT3PDGFRBKDRCSF1R
SCHEMBL4993421 0.89 NTRK1 (0.45) NTRK1HSD11B1FLT3PDGFRBKDR
SCHEMBL4994518 0.88 NTRK1 (0.44) NTRK1CHRM1FLT3PDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NTRK1 294/4885CHRM4 4564/4885CHRM1 4494/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NTRK1 294/4885CHRM4 4564/4885CHRM1 4494/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NTRK1 294/4885CHRM4 4564/4885CHRM1 4494/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NTRK1 294/4885CHRM4 4564/4885CHRM1 4494/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NTRK1 294/4885CHRM4 4564/4885CHRM1 4494/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NTRK1 294/4885CHRM4 4564/4885CHRM1 4494/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NTRK1 294/4885CHRM4 4564/4885CHRM1 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.